To: Jhild
Perhaps if your posts were more constructive, people would actually believe you were a shareholder. In watching your remarks about Boston Medical, we have yet to see anything positive. Only people who are short would be so interested in discrediting a growing company, as you have done. If you are a real shareholder, we challenge you to post your E-mail and real name on the boards for all to see. A real shareholder would not be afraid to do this. If we don't see your post of this information we should all assume you are a short seller and take all you have to say cum de salinas.
To all investors of NBMX, the company is in a transition period now and many changes are occurring. Do not be swayed by such slanderous remarks. Do your own due diligence by calling Tom Raack at Liberty Capital, 1-360-676-8072 ext. 1008.
Siv K. Ostlund
Internet Research and Relations
Liberty Capital Group, Inc.
research@libertycap.com
www.libertycap.com
This information is not a solicitation to buy or sell securities. Investors should always consult a registered investment advisor before making any investment decisions.
Liberty Capital Group (LCG) picked National Boston ("the Company") due to the tremendous growth potential in the market for antibacterial products. Additionally, LCG feels that the alliances the Company has developed over the last few months will help propel National Boston to a large and sustained revenue stream.
Due to the above, LCG has agreed to a contract with National Boston as their financial and public relations firm. LCG's contract is a full one year term and will include fees and cash of between $732,000 - $756,000. Due to huge market potential, LCG has agreed to invest up to $500,000 through an option, with prices scaled from $1.00/sh - $7.00/sh. |
